Lymphoma, Non-Hodgkin

Oncology
25
Pipeline Programs
21
Companies
24
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
9
1
12
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
350%
Monoclonal Antibody
233%
ADC
117%
+ 23 programs with unclassified modality

Competitive Landscape

21 companies ranked by most advanced pipeline stage

Biogen
BiogenCAMBRIDGE, MA
3 programs
1
1
1
ibritumomab tiuxetanPhase 41 trial
FludarabinePhase 21 trial
90Y Ibritumomab tiuxetanPhase 11 trial
Active Trials
NCT00186589Completed30Est. Jul 2007
NCT00117156Completed26Est. Jan 2012
NCT00168727Completed12Est. Oct 2005
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
3 programs
1
1
1
RituximabPhase 3Monoclonal Antibody1 trial
PalbociclibPhase 2Small Molecule1 trial
BI 836826Phase 11 trial
Active Trials
NCT01403948Completed48Est. Feb 2018
NCT02693535Recruiting4,200Est. Dec 2028
NCT02417129Terminated2Est. Dec 2015
UP
UCB PharmaBelgium - Brussels
1 program
1
Inotuzumab ozogamicinPhase 3ADC
Bayer
BayerLEVERKUSEN, Germany
2 programs
1
1
TaxanePhase 21 trial
BAY1862864Phase 11 trial
Active Trials
NCT02581878Completed21Est. Nov 2019
NCT00044551Completed29Est. Jul 2003
Pfizer
PfizerNEW YORK, NY
2 programs
1
1
PF-3512676Phase 21 trial
PF-05082566Phase 11 trial
Active Trials
NCT01307267Completed190Est. Feb 2019
NCT00880581Completed30Est. Jan 2015
Sanofi
SanofiPARIS, France
2 programs
2
G-CSF Plus PlerixaforPhase 21 trial
MitoguazonePhase 21 trial
Active Trials
NCT00322491Completed49Est. Jun 2006
NCT00002348Completed
Abbott
AbbottABBOTT PARK, IL
1 program
1
ABT-510 - Thrombospondin-1 MimeticPhase 21 trial
Active Trials
NCT00061672Completed67
Genentech
GenentechCA - Oceanside
1 program
1
FludarabinePhase 2
Novartis
NovartisBASEL, Switzerland
1 program
1
OfatumumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT01294579Completed49Est. Dec 2016
Bristol Myers Squibb
1 program
1
OlaparibPhase 2
Taiho Oncology
Taiho OncologyNJ - Princeton
1 program
1
PalbociclibPhase 2Small Molecule
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
PirtobrutinibPhase 2Small Molecule1 trial
Active Trials
NCT07162181Recruiting13Est. May 2030
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
VenetoclaxPhase 1/2
Caribou Biosciences
2 programs
1
CB-010Phase 11 trial
Caribou-sponsored investigational therapyN/A1 trial
Active Trials
NCT05332054Enrolling By Invitation150Est. Dec 2041
NCT04637763Recruiting72Est. Sep 2025
Nkarta Therapeutics
Nkarta TherapeuticsCA - South SF
1 program
1
NKX019Phase 11 trial
Active Trials
NCT05020678Active Not RecruitingEst. Dec 2038
Nektar Therapeutics
Nektar TherapeuticsSAN FRANCISCO, CA
1 program
1
TAK-659Phase 11 trial
Active Trials
NCT03772288WithdrawnEst. Nov 2021
Takeda
TakedaTOKYO, Japan
1 program
1
TAK-659Phase 11 trial
Active Trials
NCT02954406Terminated43Est. Jul 2020
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
afliberceptPhase 1
Astellas
AstellasChina - Shenyang
1 program
RibomustinN/A2 trials
Active Trials
NCT02110394Completed190Est. Aug 2015
NCT02072967Completed97Est. Oct 2015
M&
Merck & Co.RAHWAY, NJ
1 program
Standard anti-emetics in conjunction with R-CHOPN/A1 trial
Active Trials
NCT01843868Withdrawn0Est. Jun 2015
E
EisaiChina - Liaoning
1 program
Symbenda Post-Marketing Surveillance (PMS)N/A1 trial
Active Trials
NCT02434484Completed84Est. Mar 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Biogenibritumomab tiuxetan
Boehringer IngelheimRituximab
Eli Lilly and CompanyPirtobrutinib
Boehringer IngelheimPalbociclib
NovartisOfatumumab
PfizerPF-3512676
SanofiG-CSF Plus Plerixafor
BiogenFludarabine
AbbottABT-510 - Thrombospondin-1 Mimetic
BayerTaxane
Nkarta TherapeuticsNKX019
Caribou BiosciencesCB-010
Nektar TherapeuticsTAK-659
TakedaTAK-659
BayerBAY1862864

Showing 15 of 23 trials with date data

Clinical Trials (24)

Total enrollment: 5,402 patients across 24 trials

NCT00168727Biogenibritumomab tiuxetan

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

Start: Jun 2003Est. completion: Oct 200512 patients
Phase 4Completed
NCT02417129Boehringer IngelheimRituximab

BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Start: Apr 2015Est. completion: Dec 20152 patients
Phase 3Terminated
NCT00002348SanofiMitoguazone

A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma

Phase 2Completed
NCT07162181Eli Lilly and CompanyPirtobrutinib

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Start: Aug 2025Est. completion: May 203013 patients
Phase 2Recruiting
NCT02693535Boehringer IngelheimPalbociclib

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Start: Mar 2016Est. completion: Dec 20284,200 patients
Phase 2Recruiting
NCT01294579NovartisOfatumumab

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

Start: May 2011Est. completion: Dec 201649 patients
Phase 2Completed
NCT00880581PfizerPF-3512676

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Start: Jan 2009Est. completion: Jan 201530 patients
Phase 2Completed
NCT00322491SanofiG-CSF Plus Plerixafor

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Start: Mar 2004Est. completion: Jun 200649 patients
Phase 2Completed
NCT00117156BiogenFludarabine

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

Start: Dec 2003Est. completion: Jan 201226 patients
Phase 2Completed
NCT00061672AbbottABT-510 - Thrombospondin-1 Mimetic

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Start: Apr 200367 patients
Phase 2Completed
NCT00044551BayerTaxane

Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma

Start: Feb 2002Est. completion: Jul 200329 patients
Phase 2Completed
NCT05020678Nkarta TherapeuticsNKX019

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Start: Aug 2021Est. completion: Dec 2038
Phase 1Active Not Recruiting
NCT04637763Caribou BiosciencesCB-010

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Start: May 2021Est. completion: Sep 202572 patients
Phase 1Recruiting
NCT03772288Nektar TherapeuticsTAK-659

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

Start: Apr 2019Est. completion: Nov 2021
Phase 1Withdrawn
NCT02954406TakedaTAK-659

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Start: Mar 2017Est. completion: Jul 202043 patients
Phase 1Terminated
NCT02581878BayerBAY1862864

Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma

Start: Nov 2015Est. completion: Nov 201921 patients
Phase 1Completed
NCT01403948Boehringer IngelheimBI 836826

BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

Start: Aug 2011Est. completion: Feb 201848 patients
Phase 1Completed
NCT01307267PfizerPF-05082566

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Start: Jun 2011Est. completion: Feb 2019190 patients
Phase 1Completed
NCT00186589Biogen90Y Ibritumomab tiuxetan

90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

Start: May 2004Est. completion: Jul 200730 patients
Phase 1Completed
NCT05332054Caribou BiosciencesCaribou-sponsored investigational therapy

Long-Term Follow-up Study

Start: Mar 2022Est. completion: Dec 2041150 patients
N/AEnrolling By Invitation
NCT02434484EisaiSymbenda Post-Marketing Surveillance (PMS)

Symbenda Post-Marketing Surveillance (PMS)

Start: Jul 2018Est. completion: Mar 202084 patients
N/ACompleted
NCT02110394AstellasRibomustin

Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia

Start: Jun 2012Est. completion: Aug 2015190 patients
N/ACompleted
NCT02072967AstellasRibomustin

Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Start: May 2012Est. completion: Oct 201597 patients
N/ACompleted
NCT01843868Merck & Co.Standard anti-emetics in conjunction with R-CHOP

Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP

Start: Jan 2012Est. completion: Jun 20150
N/AWithdrawn

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
8m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
8m ago

Office Administrator

SystImmune
8m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
19m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
22m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
22m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 5,402 patients
21 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)